DIRS.INFO The most relevant business & tech news

☆ AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal
▼ + stars: | 2023-01-09 | by ( ) www.reuters.com time to read: 1 min

Jan 9 (Reuters) - AstraZeneca (AZN.L) said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc (CINC.O) in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs. AstraZeneca said it will pay $26 per CinCor share in cash, a premium of nearly 121% to the stock's closing price on Friday. The offer also includes a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission of CinCor's baxdrostat, which is being developed to treat cardiorenal diseases. Including this, the offer represent a 206% premium to CinCor's shares close on Friday. Reporting by Radhika Anilkumar in Bengaluru; Editing by Savio D'SouzaOur Standards: The Thomson Reuters Trust Principles.

☆ Wall Street analyst calls on Thursday including Tesla & Amazon
▼ + stars: | 2023-01-05 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Barclays names Starbucks a top 2023 pick Barclays said the coffee giant is a "best-in-class" stock for 2023. UBS names Chipotle a top 2023 pick UBS said the Mexican chain restaurant is defensive in a "tough macro." Bank of America downgrades PNC to underperform from neutral Bank of America said shares of PNC are trading at a premium. Bank of America downgrades Ally Financial to underperform from buy Bank of America said Ally is most exposed to auto loans. Bank of America reiterates Amazon as buy Bank of America said Amazon layoffs are "not a positive signal, but good for sentiment."

☆ Companies Spend Record Amounts on Dividends, Despite Looming Downturn
▼ + stars: | 2022-12-30 | by ( Mark Maurer | ) www.wsj.com time to read: +7 min

They usually review their cash flow expectations for at least the next 18 months when determining whether or how much to pay in dividends, Mr. Silverblatt said. Of the S&P 500, 373 companies raised dividends in 2022 through Dec. 15, compared with 353 in 2021, according to S&P Dow Jones Indices. Five S&P 500 companies decreased their dividend in 2022 through Dec. 15, compared with four in 2021. It paid $7 billion in cash dividends for the year ended Oct. 30, up 13.2% from the prior-year period. Cash and cash equivalents totaled $505.5 million as of Sept. 30, down from $673 million a year earlier, filings showed.

☆ Stocks making the biggest moves midday: Netflix, Cal-Maine Foods, Southwest and more
▼ + stars: | 2022-12-29 | by ( Samantha Subin | ) www.cnbc.com time to read: +2 min

Cal-Maine Foods — Cal-Maine shares shed 15% after reporting earnings that fell short of Wall Street's expectations even as the egg producer reported record sales. Southwest Airlines — The airline stock rose more than 3%, paring back losses from the previous session when it dropped more than 5%. Severe disruptions at Southwest Airlines have drawn outsized criticism from frustrated travelers, who have dealt with thousands of canceled flights from airlines this week because of winter weather. Southwest Airlines canceled another 60% of its flights on Wednesday. Apple — The iPhone maker's stock rose more than 3% after hitting its lowest level since June 2021 earlier in the week.

☆ Stocks making the biggest moves midday: Tesla, Southwest, Apple, AMC and more
▼ + stars: | 2022-12-28 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Shares of AMC Entertainment more than quadrupled today as investors continue their buying spree on heavily shorted stocks. Baird also trimmed its price target on shares to $252 from $316 a share. AMC Entertainment – AMC Entertainment shares dipped about 3% a day after CEO Adam Aron tweeted that he asked the company's board to freeze his 2023 pay and urged other executives to forgo salary bumps. Maxeon — Shares slid 8% after the solar company announced Bill Mulligan would be the new CEO. The firm gave the stock a price target of $29, which presents an upside of 75.4% over where it closed Tuesday.

☆ The Dow's best and worst performers of 2022 — and where analysts see the stocks going from here
▼ + stars: | 2022-12-26 | by ( Alex Harring | ) www.cnbc.com time to read: +4 min

Ten of the 30 stocks in the average are on track to end the year with gains as of Friday, according to FactSet. Here are the best and worst performing stocks in the index this year and what analysts think is coming next. In all, 61% of analysts rate the stock a hold with a price target that implies a 15.2% upside. Still, analysts like the stock, with the average price target showing a 50.8% upside. More than four-fifths, or 82%, of analysts rate the stock overweight or buy, with an expected upside of 35.9%.

☆ Lab-grown meat could be served up for dinner soon. What does it taste like?
▼ + stars: | 2022-12-19 | by ( Julia Horowitz | ) edition.cnn.com time to read: +11 min

It has a capacity of 600 liters, or 159 gallons, allowing the company to produce 6,000 pounds of cultivated meat per year. Right now, Singapore is alone in allowing the sale of cultivated meat to consumers, having issued a green light in late 2020. Yet delivering on the promise of lab-grown meat won’t just come down to regulators. CNN“The promise of cultivated meat [is] to bring forth a taste and texture component, and to deliver sustainability,” said Gautam Godhwani, managing partner at Good Startup, a Singapore-based venture capital firm that has invested in eight cultivated meat startups. “I think the whole of the cultivated meat industry will go hybrid first,” Ivy Farm’s Dillon said.

☆ Amgen to buy Horizon Therapeutics for $116.50 per share
▼ + stars: | 2022-12-12 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAmgen to buy Horizon Therapeutics for $116.50 per shareAmgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, in a deal valued at approximately $26.4 billion.

Come next year, Democrats will have unilateral subpoena power in many committees to compel investigative targets to provide documents and testimony — without needing GOP support. “Our committees will have greater oversight ability, subpoena power. Subpoena power can deal with corporate corruption and inequities, and other problems throughout the country,” he said. “And if using subpoena power becomes necessary, then that’s something we can do.”Other Democrats floated industries that could be the targets of the party's subpoena powers. “But having subpoena power for CEOs and billionaires who think they don’t have to come to Congress to explain themselves will be very valuable.”

☆ I left a high-powered job at Google to launch my own startup, and I've never been happier
▼ + stars: | 2022-12-09 | by ( Julie Bort | ) www.businessinsider.com time to read: +5 min

Melody Meckfessel, the CEO-cofounder of Observable, spent 14 years at Google, rising to a VP role. It was the most thrilling job for a person like me who loves to build software that people find useful. At Google, I worked on search, data tools, and systems that Google was using to bring data centers online. But I couldn't see the path to build that idea within my job at Google. In early 2019, after years of thinking about this data platform idea, I knew I needed to go do this next thing.

☆ Stocks making the biggest moves midday: Tesla, VF Corp, Marriott, MGM and more
▼ + stars: | 2022-12-05 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

United Airlines , Delta Airlines – United gained 4% following a Morgan Stanley upgrade to overweight from equal weight on the notion that 2023 could be a "goldilocks" year for the airline. Silvergate Capital — Shares dropped more than 5% after Morgan Stanley downgraded the crypto bank to underweight from equal weight, saying there is more revenue pressure following the FTX fallout. Signature Bank — The stock declined more than 7% after Morgan Stanley downgraded it to equal weight from overweight. Morgan Stanley expects funding costs to jump "significantly" over the next several quarters as Signature works to retain deposits from customers. Many Chinese stocks pared earlier gains, however, as the broader market sold off amid fears of aggressive monetary tightening.

☆ Goldman Sachs says this little-known biotech stock can double on potentially ‘blockbuster’ revenue
▼ + stars: | 2022-12-01 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Investors should buy biopharma stock Altimmune as it can double from here depending on the success of a new obesity drug, according to Goldman Sachs. However, the analyst expects that the growing obesity market is not a "zero-sum game" and has niches for new players. "We believe that cardiovascular and lipid benefits conferred by pemvidutide will allow ALT to earn meaningful market share and blockbuster revenues," Jenkins wrote. The analyst expects further studies on the pemvidutide's treatment on other diseases could also help differentiate the drug. Shares of Altimmune are up 8% this year, but the analyst expects they'll advance further.

☆ Here are Thursday's biggest analyst calls: Apple, Amazon, Tesla, Chipotle, Capital One, United & more
▼ + stars: | 2022-12-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Morgan Stanley downgrades Capital One and Ally Financial to underweight from equal weight Morgan Stanley said in its downgrade of Capital One and Ally Financial that it sees "significant risk" for both stocks. Morgan Stanley reiterates Tesla as overweight Morgan Stanley said it's standing by it's overweight rating on Tesla but is concerned 2023 could be a disappointing year in general for electric vehicles. Morgan Stanley initiates Vizio as equal weight Morgan Stanley said it's concerned the television tech company lacks scale to keep up with bigger competitors. Morgan Stanley reiterates Salesforce as overweight Morgan Stanley said it's standing by shares of Salesforce after the company's disappointing earnings report on Wednesday. Morgan Stanley reiterates Snowflake as overweight Morgan Stanley said investors should stick with shares of Snowflake for the long-term after its earnings report on Wednesday.

☆ FASB Again Aims for More Disclosure on Taxes From U.S. Companies
▼ + stars: | 2022-11-30 | by ( Mark Maurer | ) www.wsj.com time to read: +5 min

The Financial Accounting Standards Board on Wednesday said it wants companies to provide more information on their income taxes, the group’s latest attempt to give the public more detail on the companies they invest in. At least once a year, public companies have to disclose the amount of cash taxes they pay. Companies must also disclose their effective tax rate, or the ratio between their tax expense and their pretax income. The first proposal came in 2016 and would have required companies to distinguish their U.S. from their foreign income taxes, among other changes. This time, it sought a breakout of the amount of federal, state and foreign taxes public companies paid, as well as disclosure on a quarterly basis.

☆ It's 'early innings' in the fertility market. Here's how to play the booming business with under-the-radar names
▼ + stars: | 2022-11-17 | by ( Michelle Fox | ) www.cnbc.com time to read: +13 min

The multibillion dollar global fertility market is ripe with opportunity. For investors thinking about the fertility market, pharma firms may come to mind. In fact, the number of employers looking at fertility benefits as a "must have" has skyrocketed, she said. The global market size for fertility within the private women's health market should reach $72 billion by 2027, a report by FemTech Focus and Coyote Ventures found. Just like there were a wave of fintech companies going public, she expects fertility companies to eventually follow suit.

☆ Stocks making the biggest moves midday: Bath & Body Works, Norwegian Cruise Line, Macy's and more
▼ + stars: | 2022-11-17 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Bath & Body Works – Bath & Body Works' stock surged 24% after reporting per-share earnings that were more than double what analysts had anticipated. The retailer also raised its guidance for full-year per-share earnings. Norwegian Cruise Line – Shares of the cruise stock shed 6% following a double downgrade to an underperform rating from Credit Suisse. Macy's – Shares of Macy's rallied 14% after the department store reported profit and revenue that beat Wall Street's expectations. BJ's Wholesale – Shares dropped 6% despite the company reporting beats on the top and bottom lines and raising its full-year forecast for per-share earnings.

☆ The fund manager who's in the green this year by not playing 'the relative game'
▼ + stars: | 2022-11-14 | by ( Alex Harring | ) www.cnbc.com time to read: +7 min

J. Dale Harvey, founder and chief investment officer at Poplar Forest, manages a fund that's beating the S & P 500 this year. Harvey has led the Poplar Forest Partners Fund (PFPFX) since it was established on Dec. 31, 2009 with a "contrarian" mindset. "People can get sucked into the sort of the relative game, which which we don't play," he said. The fund took a dip with the rest of the market in September before marching back up in the following weeks. He noted value stocks, where he mainly looks, were "in the doghouse" for much of the 2010s as technology and other growth stocks drove the market.

☆ Wells Fargo says buy small caps over large caps. Here are 10 favorites
▼ + stars: | 2022-11-08 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Small-cap stocks in Wells Fargo's portfolio are poised to outperform their larger counterparts. "Last year we said small-cap Quality was historically mispriced, but did not think the macro environment favored small caps over large caps," he said in a Monday note to clients. "Going forward, we still believe in a High Quality approach, and we now expect small caps to outpace large caps." Harvey said small caps are technically oversold, but they are beginning to "bounce" while having "more attractive" valuations. The portfolio includes about three dozen stocks that Wells Fargo calls "high quality" small caps.

☆ Companies tout dividend strength on earnings calls. One stock raising payout for 48th straight year
▼ + stars: | 2022-11-04 | by ( Alex Harring | ) www.cnbc.com time to read: +5 min

Dividends have become increasingly important to investors in the choppy stock market and executives know it, trumpeting their payouts during earnings calls. The data processor beat expectations on per-share earnings and revenue for its first quarter when reporting Oct. 26 . The company beat expectations on per-share earnings while missing on revenue. 'A high priority' Southwest Airlines is trying to once again be a dividend stock. The airline beat expectations for per-share earnings and revenue, which hit a company record at $6.22 billion .

☆ JPMorgan says these 8 energy stocks have huge 'upside potential' amid painful rate hikes – and breaks down 2 others that allows investors to cash in near-term
▼ + stars: | 2022-11-02 | by ( Morgan Chittum | ) www.businessinsider.com time to read: +3 min

While the S&P 500 is down nearly 20% year-to-date, its energy sector is up about 60% so far in 2022. JPMorgan recommends these 8 Russell 2000-listed energy stocks amid a harsh macro backdrop. Amid the central bank's monetary tightening to combat near 40-year high inflation, stocks continue their downtrend. Energy stocks, in particular, could be a nice buying opportunity as the US economy appears to be heading toward a recession. With a mix of both growth and value stocks, JPMorgan recommends these 10 Russell 2000-listed stocks amid harsh macro conditions.

☆ New U.S. cancer drug prices rise 53% in five years -report
▼ + stars: | 2022-11-02 | by ( Deena Beasley | ) www.reuters.com time to read: +4 min

"I do think there is a possibility we see launch prices go up," she said. Reuters GraphicsPorter, who championed inflation-based caps on drug prices, is calling for additional national legislation to link launch prices to how well a drug works. The report found that the average launch price of a self-administered cancer drug, after adjusting for inflation, rose by nearly 26% to $238,000 between 2017 and 2021. By 2022, six out of the eight newly-launched oral cancer drugs had prices over $200,000 per year. Based on current trends, the report calculated that by 2026, when Medicare will first be able to negotiate drug prices, the average self-administered cancer drug launch price will be nearly $325,000 per year and over $525,000 for pills and biologics.

☆ J&J's nearly $17 billion offer to buy a heart pump maker goes right to why we own it
▼ + stars: | 2022-11-01 | by ( Zev Fima | ) www.cnbc.com time to read: +7 min

The spin-off of J & J's consumer business, including such brands as Band-Aid and Tylenol, is expected in November of next year. Bottom line The new standalone J & J consumer company will be called Kenvue . A decision like this, to lay out nearly $17 billion, or $380 per Abiomed share, upfront, can therefore speak to management's confidence in the opportunity this acquisition presents. Fortunately, Johnson & Johnson has one of the best balance sheets in the world. Johnson & Johnson headquarters in New Brunswick, N.J. Mel Evans | AP

☆ Here are Monday's biggest analyst calls: Tesla, Apple, Southwest, Uber, Roku, Home Depot, AMD & more
▼ + stars: | 2022-10-31 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

UBS downgrades Caterpillar to neutral from buy UBS said in its downgrade of Caterpillar that it sees a more "balanced risk/reward." Morgan Stanley upgrades Pure Storage to overweight from equal weight Morgan Stanley said in its upgrade of the data flash storage company that it sees "share gains and growing value proposition." Morgan Stanley reiterates Southwest as a top pick Morgan Stanley says it has "solid confidence" in shares of Southwest. Morgan Stanley reiterates Charles Schwab as a top pick Morgan Stanley says it's standing by the stock despite shares underperforming. Oppenheimer reiterates Uber as outperform Oppenheimer says Uber shares have a "compelling value proposition" ahead of earnings on Tuesday.

☆ 3 takeaways from our daily meeting: Looking for new stocks, 2 trades, earnings recap
▼ + stars: | 2022-10-28 | by ( Krystal Hur | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. We made 2 trades We are exiting our position in Abbvie (ABBV) and buying more shares of Starbucks (SBUX). As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Stocks making the biggest moves midday: Avis, Pinduoduo, Starbucks, Alibaba and more
▼ + stars: | 2022-10-24 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

People wait in line at Avis rental agency in the Miami International Airport Car Rental Center. Starbucks — Starbucks' shares dropped more than 5% in midday trading. Avis Budget Group — Shares of the rental car company jumped more than 12% after being upgraded by JPMorgan to overweight from neutral. Analysts believe car rental prices will remain elevated longer than investors believe. Tractor Supply Company — Shares of Tractor Supply Company rose 5.5% along with the market.

Search resuls for: "Biopharmaceutical"

25 mentions found